Evidence map›Paper›PMID 38304182›Full record

ArticleFrontiers in public health2024

The positivity rates and drug resistance patterns of

Xusheng Gao, Tongxia Li, Wenge Han, Yu Xiong, Shiyang Xu, Hongbao Ma, Qing Wang, Qiuxia Zhang, Guofeng Yang, Dan Xie and 10 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Rapid detection of rifampin resistance inMicrobiology spectrum · 2025
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Xusheng Gao *Department of Tuberculosis, Shandong Public Health Clinical Center, Shandong University, Jinan, Shandong, China.
Tongxia Li *Department of Tuberculosis, Qingdao Chest Hospital, Qingdao, Shandong, China.
Wenge Han *Department of Tuberculosis, Weifang Second People's Hospital, Weifang, Shandong, China.
Yu Xiong *Department of Tuberculosis, Shandong Public Health Clinical Center, Shandong University, Jinan, Shandong, China.
Shiyang XuDepartment of Tuberculosis, Dezhou Second People's Hospital, Dezhou, Shandong, China.
Hongbao MaDepartment of Tuberculosis, Yantai Pulmonary Hospital, Yantai, Shandong, China.
Qing WangDepartment of Tuberculosis, Shandong Public Health Clinical Center, Shandong University, Jinan, Shandong, China.
Qiuxia ZhangDepartment of Internal Medicine, Zaozhuang Tumor Hospital, Zaozhuang, Shandong, China.
Guofeng YangDepartment of Tuberculosis, Liaocheng Infectious Disease Hospital, Liaocheng, Shandong, China.
Dan XieDepartment of Tuberculosis, Shandong Public Health Clinical Center, Shandong University, Jinan, Shandong, China.
Peipei JiangDepartment of Tuberculosis, Shandong Public Health Clinical Center, Shandong University, Jinan, Shandong, China.
Hailiang WuDepartment of Tuberculosis, Shandong Public Health Clinical Center, Shandong University, Jinan, Shandong, China.
Mei LinDepartment of Tuberculosis, Qingdao Chest Hospital, Qingdao, Shandong, China.
Min LiuDepartment of Respiratory Medicine, Tai'an Tumor Prevention and Treatment Hospital, Tai'an, Shandong, China.
Mingde NiDepartment of Tuberculosis, Linyi People's Hospital, Linyi, Shandong, China.
Decui WangDepartment of Tuberculosis, Binzhou Central Hospital, Binzhou, Shandong, China.
Ying LiDepartment of Internal Medicine, Zibo First Hospital, Zibo, Shandong, China.
Lunxian JiaoThird Department of Respiratory Medicine, Yantai Beihai Hospital, Yantai, Shandong, China.
Caihong DingDepartment of Tuberculosis, Shandong Public Health Clinical Center, Shandong University, Jinan, Shandong, China.
Zhongfa ZhangRespiratory Center, Shandong Public Health Clinical Center, Shandong University, Jinan, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the positivity rates and drug resistance characteristics of Methods: A prospective, multi-center study was conducted from April 2022 to June 2023. Pathogen and drug resistance were identified using nucleotide matrix-assisted laser desorption ionization time-of-flight mass spectrometry (nucleotide MALDI-TOF MS). Results: Of 940 suspected TB patients included in this study, 552 cases were found to be infected with MTB giving an overall positivity rate of 58.72%. Total of 346 cases were resistant to arbitrary anti-TB drug (62.68%), with Zibo (76.47%), Liaocheng and Weihai (both 69.23%) ranking top three and TB treatment history might be a related factor. Monoresistance was the most common pattern (33.53%), with isoniazid the highest at 12.43%, followed by rifampicin at 9.54%. Further analysis of gene mutations conferring resistance revealed diverse types with high heteroresistance rate found in multiple anti-TB drugs. Conclusion: A relatively high rate of MTB positivity and drug resistance was found in Shandong Province during and after the COVID-19 pandemic, indicating the need for strengthening rapid identification of species and drug resistance among suspected TB patients to guide better medication and minimize the occurrence of drug resistance.

Indexed as

Mycobacterium tuberculosisTuberculosisAntitubercular AgentsHumansNucleotidesPandemicsProspective StudiesSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationAntitubercular AgentsNucleotidesdrug resistancemutationnucleotide MALDI-TOF MSShandong Provincetuberculosis

Identifiers

PMID38304182
PMCPMC10830759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.